Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company''s lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Latest shares articles
Inflation in focus this week as markets will want to gauge whether the Federal Reserve will be able to lower rates next month
Inflation in focus this week as markets will want to gauge whether the Federal Reserve will be able to lower rates next month
23 hours ago
Natural Gas hovers near critical $3 level
Natural gas prices toy with the $3 mark as sellers struggle to achieve a close beneath the crucial support level
10:01, 7 August 2025
Gold (XAU/USD) remains supported as economic concerns resurface
Safe haven interest drives gold higher as markets no expect the Federal Reserve to cut rates in September
11:16, 6 August 2025
Bank of England Preview: Further easing expected
The Bank of England is expected to lower rates by 25 bps in August but the vote split may give markets further insight into the MPC's outlook
09:31, 5 August 2025
Ratings and Reviews
Ratings and Reviews
